Clinical trials: Giant Cell Arteritis (GCA)
Large Vessel Vasculitis, Takayasu Arteritis
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
Large vessel vasculitis (LVV) is an autoimmune inflammatory disorder affecting the major arteries of the body. The diagnosis and monitoring this condition can be challenging, as patients often present with symptoms that are…
- Conditions
- Large Vessel Vasculitis, Takayasu Arteritis, Giant Cell Arteritis (GCA)
- Trial name
- LAVA-FLOW (NCT07628075)
- Testing
- [18F]FDG Long-Axial Field of View (LAFOV)-PET/CT, CT Angiogram, MR Angiogram
- Where
- 3 sites in United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Giant Cell Arteritis (GCA)
Disease Activity Monitoring in Patients With Giant Cell Arteritis Study
Giant Cell Arteritis (GCA) is a vasculitis of medium- and large-sized arteries in older adults that may lead to serious vascular complications, including permanent vision loss and aortic aneurysm formation.
- Trial name
- DiAcMo (NCT07552636)
- Where
- 7 sites in Denmark
- Volunteers
- 175 people
- Sponsor
- University of Aarhus
Giant Cell Arteritis (GCA)
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
This is a multi-center, randomized, open label study that will assess the efficacy and safety of ACTEMRA(R) or one of its FDA-approved biosimilars Tocilizumab (TCZ) maintenance versus withdrawal in Giant cell arteritis (GCA)…
- Trial name
- NCT07108387
- Testing
- Tocilizumab, Discontinue Tocilizumab
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Giant Cell Arteritis (GCA)
Kinetics of C-Reactive Protein in Giant Cell Arteritis Following Glucocorticoid Initiation: A Pilot Study (GIDEON)
We propose to analyze the kinetics of the main marker of inflammation in GCA in order to understand its links with initial clinical manifestations and the possible appearance of complications and/or relapses.
- Trial name
- GIDEON (NCT07720804)
- Testing
- Blood tests to measure CRP
- Volunteers
- 40 people
- Sponsor
- University Hospital, Limoges
Giant Cell Arteritis (GCA), Doppler Ultrasound
Halo Sign Vanishing Time After Steroids Outbreak in GCA Patients
Giant cell arteritis (GCA) is a rare disease characterized by vasculitis of the large arterial trunks targeting the thoracic aorta and its dividing branches, affecting adults over the age of 50.
- Trial name
- Halo-A (NCT07060274)
- Testing
- Doppler Ultrasound
- Where
- 6 sites in France
- Volunteers
- 64 people
- Sponsor
- Centre Hospitalier le Mans
Giant Cell Arteritis (GCA)
Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA)
B cells are a component of the immune system which appear be important in causing all forms of cardiovascular disease. Until now, it has not been possible to directly study these cells in living patients (essential to assess…
- Trial name
- RituxiMAP GCA (NCT07269938)
- Testing
- Zirconium Zr 89 labelled rituximab
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Giant Cell Arteritis (GCA), Ischemic Optic Neuropathy
Orbital Vascular Inflammation in Ischemic Optic Neuropathy and Giant Cell Arteritis
Giant cell arteritis (GCA) is an inflammation of the blood vessels. A dangerous complication is sudden vision loss due to insufficient blood supply to the optic nerve.
- Conditions
- Giant Cell Arteritis (GCA), Ischemic Optic Neuropathy, NAION - Non-Arteritic Ischemic Optic Neuropathy
- Trial name
- VISION-GCA (NCT07206238)
- Testing
- Positron Emission Tomography / Magnetic Resonance Imaging
- Where
- Denmark
- Volunteers
- 122 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Giant Cell Arteritis (GCA)
Bosentan in the Treatment of Giant Cell Arteritis
The purpose of this study is to determine whether a treatment with 3 months of bosentan associated to standard therapy might be superior to glucocorticoids alone in term of failure free survival at 12 months
- Trial name
- BOSICART (NCT06957002)
- Testing
- Bosentan, Glucocorticoids
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Giant Cell Arteritis (GCA)
Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone
The GISCO study plans to determine whether 8-week therapy is just as effective as 26-week cortisone therapy for treating giant cell arteritis with tocilizumab, while using less cortisone.
- Trial name
- GISCO (NCT06833411)
- Testing
- Prednisone
- Where
- Switzerland
- Volunteers
- 178 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Giant Cell Arteritis (GCA)
The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant Cell Arteritis.
Giant cell arteritis (GCA) is the most common vasculitis in the elderly and is usually treated with long-term corticosteroid therapy. Many patients experience relapses and treatment-related side effects.
- Trial name
- NCT07246577
- Where
- Sweden
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Giant Cell Arteritis (GCA)
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
- Trial name
- GCAptAIN (NCT04930094)
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 104 sites in United States, Argentina and 25 more
- Volunteers
- 354 people
- Sponsor
- Novartis Pharmaceuticals
Giant Cell Arteritis (GCA), Cardiovascular Diseases
TArget Trial Emulation Comparing Effectiveness of Tocilizumab vs Methotrexate In Corticosteroid-Treated GCA Patients
This nationwide observational study emulates a target trial to compare the effect of tocilizumab versus methotrexate initiation on major adverse cardiovascular events (MACE) in patients with incident giant cell arteritis using…
- Trial name
- TACTIC-GCA (NCT07459335)
- Where
- 2 sites in France
- Volunteers
- 1,667 people
- Sponsor
- Groupe français d'étude des Maladies Inflammatoires de loeil
Giant Cell Arteritis (GCA)
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper…
- Trial name
- SELECT-GCA (NCT03725202)
- Testing
- Upadacitinib, Corticosteroid (CS)
- Where
- 172 sites in United States, Australia and 22 more
- Volunteers
- 429 people
- Sponsor
- AbbVie
Giant Cell Arteritis (GCA), Spondylarthritis
Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica
The purpose of the study is to recruit as many patients as possible presenting with sacroiliitis or authentic axial spondylarthritis and giant cell arteritis.
- Conditions
- Giant Cell Arteritis (GCA), Spondylarthritis, Polymyalgia Rheumatica
- Trial name
- SAGE PPR (NCT07394478)
- Testing
- Description of population
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- Hôpital NOVO
Giant Cell Arteritis (GCA)
Upadacitinib in Giant Cell Arteritis (GCA) With Active Large-vessel Involvement.
Participants will be followed as part of the usual management of their disease. No modifications will be made (no additional visits, examinations, or questionnaires).
- Trial name
- TILT2 (NCT07354906)
- Where
- 14 sites in France
- Volunteers
- 80 people
- Sponsor
- Groupe français d'étude des Maladies Inflammatoires de loeil
Large Vessel Vasculitis, Giant Cell Arteritis (GCA)
Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
Large vessel vasculitis (LVV) is a disease that causes damage to blood vessels. This damage to blood vessels can increase the risk of patients with LVV developing cardiovascular disease, including heart attacks and strokes.
- Conditions
- Large Vessel Vasculitis, Giant Cell Arteritis (GCA), Takayasu Arteritis
- Trial name
- DERAIL-LVV (NCT06887062)
- Testing
- Bosentan and dapagliflozin
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Adrenal Insufficiency, Polymyalgia Rheumatica (PMR)
Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment
Cortisol, a glucocorticoid (GC) hormone secreted from the adrenal glands, is essential for survival. Cortisol also possesses anti-inflammatory actions and GC formulations (prednisolone) are used to treat many inflammatory…
- Conditions
- Adrenal Insufficiency, Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)
- Trial name
- REPLACE (NCT05193396)
- Testing
- Hydrocortisone
- Where
- 3 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Marianne Andersen
Giant Cell Arteritis (GCA)
oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound
The purpose of this study is to evaluate whether the measure of the optic nerve sheath is a reliable diagnostic marker for giant cell arteritis
- Trial name
- PETRUS (NCT07001059)
- Testing
- orbital ultrasound
- Where
- 9 sites in France
- Volunteers
- 190 people
- Sponsor
- Hôpital NOVO
Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR)
Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)
Polymyalgia rheumatica (PMR) is a rheumatologic condition occurring in patients > 50 years old, characterized by inflammatory pain of the scapular (shoulder) and pelvic (hip) girdles.
- Trial name
- THROPIQ (NCT06609668)
- Testing
- Additional blood samples
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Rheumatic Diseases, Rheumatoid Arthritis (RA)
Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy
The CARe RAiSE project represents a pioneering translational initiative aimed at advancing precision medicine in the treatment of autoimmune rheumatic diseases.
- Conditions
- Rheumatic Diseases, Rheumatoid Arthritis (RA), Giant Cell Arteritis (GCA), Psoriatic Arthritis (PsA)
- Trial name
- CARe RAiSE (NCT07150000)
- Testing
- Ex Vivo Assay
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Bonn